If successful, the resulting antigen-targeted EVOC Probes will have the potential for use in pre-clinical research to support both cell-based and in-vivo studies; in clinical trials for patient stratification and measurement of target engagement; and as companion diagnostics to identify responders/non-responders for therapy selection and to measure target engagement over the course of treatment.
Owlstone is developing diagnostic tests in areas of high unmet clinical need including for the early detection of lung cancer, the most common cancer in the world. To support this effort, Owlstone has pioneered the use of EVOC Probes1 in early detection and precision medicine, with the Company’s lead EVOC Probe in clinical trials. This probe utilizes the activity of enzymes expressed within the tumor microenvironment to release a volatile reporter chemical that can be detected on breath when a tumor is present. The combined approach to be explored under the Agreement will exploit Bicycle’s proprietary Bicycle technology to direct binding and accumulation of the probe on tumor cells, following which increased levels of the reporter chemical would be released.
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are committed at Owlstone to transforming diagnostics through the earlier detection of disease through breath, and are always seeking innovative approaches to further enhance the performance of our tests. Through our partnership with Bicycle, we will jointly explore the exciting possibilities of a combined antigen-targeted EVOC approach for a broad range of precision medicine applications, initially for the early detection of lung cancer to support Owlstone’s ongoing work in this area.”